Abeona Therapeutics Inc. (ABEO)

4.6000 +0.5300 (+13.02%) 收市：04:00PM EDT

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103
United States
646 813 4701
https://www.abeonatherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 84

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Vishwas Seshadri M.B.A., Ph.D.	President, CEO & Director	1.49M	無	1976
Mr. Joseph Walter Vazzano C.P.A.	Chief Financial Officer	920.85k	無	1984
Dr. Brendan M. O'Malley J.D., Ph.D.	Senior VP & General Counsel	802.95k	無	1970
Mr. Brian Kevany Ph.D.	Senior VP, CTO & CSO	無	無	無
Mr. Gregory Gin	Vice President of Investor Relations & Corporate Communications	無	無	無
Ms. Alison Hardgrove	Vice President of Human Resources	無	無	無
Mr. Jon Voss	VP & Head of Quality	無	無	1960
Mr. Dmitriy Grachev M.D., Ph.D.	Chief Medical Officer	無	無	無
Dr. Madhav Vasanthavada M.B.A., Ph.D.	Senior VP, Chief Commercial Officer & Head of Business Development	無	無	無
Mr. Carl Denny	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

公司管治

截至 無 止，Abeona Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。